Literature DB >> 12849652

Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials.

C Michael Gibson1, Juhana Karha, Sabina A Murphy, David James, David A Morrow, Christopher P Cannon, Robert P Giugliano, Elliott M Antman, Eugene Braunwald.   

Abstract

OBJECTIVES: We hypothesized that early recurrent myocardial infarction (MI) following fibrinolytic administration would be assessed with higher mortality at both 30 days and 2 years.
BACKGROUND: Although early recurrent MI after fibrinolytic therapy has been associated with increased early mortality in the acute MI setting, its relation to long-term mortality has not been fully explored.
METHODS: Mortality data were ascertained in 20,101 patients enrolled in the Thrombolysis In Myocardial Infarction (TIMI) 4, 9, and 10B and Intravenous NPA for the Treatment of Infarcting Myocardium Early (InTIME-II) acute MI trials.
RESULTS: The frequency of symptomatic recurrent MI during the index hospitalization was 4.2% (836/20,101). Recurrent MI during the index hospital period was associated with increased 30-day mortality (16.4% [137/836] vs. 6.2% [1,188/19,260], p < 0.001). Likewise, recurrent MI was associated with a sustained increase in mortality up to two years, even after adjustments were made for covariates known to be associated with mortality and recurrent MI (hazard ratio 2.11, p < 0.001). However, this higher mortality at 2 years was due to an early divergence in mortality by 30 days and was not due to a significant increase in late mortality between 30 days and 2 years (4.38% [31/707] vs. 3.76% [685/18,206], p = NS). Percutaneous coronary intervention during the index hospitalization was associated with a lower rate of in-hospital recurrent MI (1.6% vs. 4.5%, p < 0.001) and lower two-year mortality (5.6% vs. 11.6%, p < 0.001). Performance of coronary artery bypass graft surgery was also associated with a lower recurrent rate of MI (0.7% vs. 4.3%, p < 0.001) and lower two-year mortality rate (7.95% vs. 10.6%, p = 0.0008).
CONCLUSIONS: Early recurrent MI is associated with increased mortality up to two years. However, most deaths occur early, and the risk of additional deaths between the index hospital period and two years was not significantly increased among patients with recurrent MI. Percutaneous coronary intervention during the index hospitalization was associated with a lower risk of recurrent MI and a lower risk of two-year mortality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12849652     DOI: 10.1016/s0735-1097(03)00506-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  20 in total

Review 1.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

2.  Patient-centered imaging.

Authors:  E Gordon Depuey; John J Mahmarian; Todd D Miller; Andrew J Einstein; Christopher L Hansen; Thomas A Holly; Edward J Miller; Donna M Polk; L Samuel Wann
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

3.  Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002.

Authors:  P Buch; S Rasmussen; G H Gislason; J N Rasmussen; L Køber; N Gadsbøll; S Stender; M Madsen; C Torp-Pedersen; S Z Abildstrom
Journal:  Heart       Date:  2006-08-29       Impact factor: 5.994

4.  Risk stratification after acute myocardial infarction: is it time to reassess? Implications from the INSPIRE trial.

Authors:  John J Mahmarian; Craig M Pratt
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

5.  Bleeding complications after contemporary pharmacoinvasive therapy for ST elevation myocardial infarction.

Authors:  Matthew J Gutierrez; Atul Aggarwal; Kristin Gilbert; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

6.  Elevated serum YKL-40 level predicts myocardial reperfusion and in-hospital MACE in patients with STEMI.

Authors:  M Cetin; S A Kocaman; A Canga; A Kırbaş; A Yılmaz; T Erdoğan; O Akgül; Y Uğurlu; M E Durakoğlugil
Journal:  Herz       Date:  2012-09-08       Impact factor: 1.443

7.  Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection.

Authors:  Vikas Singh; Mauricio G Cohen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-05

Review 8.  Evaluation and Management of ST-elevation Myocardial Infarction and Shock.

Authors:  Lee Chang; Robert Yeh
Journal:  Eur Cardiol       Date:  2014-12

9.  Adenosine sestamibi SPECT post-infarction evaluation (INSPIRE) trial: A randomized, prospective multicenter trial evaluating the role of adenosine Tc-99m sestamibi SPECT for assessing risk and therapeutic outcomes in survivors of acute myocardial infarction.

Authors:  John J Mahmarian; Leslee J Shaw; Gerald H Olszewski; Bradley K Pounds; Maria E Frias; Craig M Pratt
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

10.  The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome.

Authors:  Peter C Kievit; Marc A Brouwer; Gerrit Veen; Wim R M Aengevaeren; Freek W A Verheugt
Journal:  J Thromb Thrombolysis       Date:  2008-06-26       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.